Decreased Expression of Cytotoxic T Lymphocyte-associated Protein 4: A Risk Factor of Myocardial Infarction
,
Abstract
Cardiovascular diseases are the most prevalent disease worldwide and pose a considerable threat to human health. Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) plays a crucial role in the maintenance of immune diseases; however, its role in the progression of cardiovascular disorders is still unknown. The present study aimed to evaluate the relationship between CTLA-4 and myocardial infarction (MI).
The Kyoto encyclopedia of genes and genomes database and the pathway studio database has revealed the role of CTLA4 as an inhibitory receptor on activated T cells. The relative expression of the CTLA-4 gene was assessed on the peripheral blood cells in 80 MI patients and 80 healthy individuals using quantitative real-time polymerase chain reaction (qRT-PCR) and also receiver operating characteristic (ROC) analysis was performed to evaluate the sensitivity and specificity of CTLA-4.
We noticed the decreased expression of CTLA-4 levels in patients, compared to the control group (2.73±1.55 vs. 5.36±1.34). The study revealed the sensitivity of 0.89, specificity of 0.83, the accuracy of 0.9, and the area under the ROC curve (AUC) of 0.901 (95% CI: 0.727-0.776) for CTLA-4.
The results highlighted the critical role of CTLA-4 as an inhibitory receptor in the maintenance of cardiovascular risks.
2. Maciejak A, Kiliszek M, Michalak M, Tulacz D, Opolski G, Matlak K, et al. Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Med. 2015;7(1):26.
3. Gholikhani-Darbroud R, Khaki-Khatibi F, Mansouri F, Hajahmadipoorrafsanjani M, Ghojazadeh M. Decreased circulatory microRNA-4478 as a specific biomarker for diagnosing non-ST-segment elevation myocardial infarction (NSTEMI) and its association with soluble leptin receptor. Bratisl Lek Listy. 2017;118(11):684-90.
4. Mansouri F, Seyed Mohammadzad MH. Up-Regulation of Cell-Free MicroRNA-1 and MicroRNA-221-3p Levels in Patients with Myocardial Infarction Undergoing Coronary Angiography. Adv Pharm Bull, 2021; 11(4): 719-727 .
5. Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol. 2013;167(2):531-6.
6. Ward JA, Esa N, Pidikiti R, Freedman JE, Keaney JF, Tanriverdi K, et al. Circulating Cell and Plasma microRNA Profiles Differ between Non-ST-Segment and ST-Segment-Elevation Myocardial Infarction. Fam Med Med Sci Res. 2013;2(2):108-16.
7. Mansouri F, Seyed Mohammadzad MH. Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis. Asian Pac J Cancer Prev. 2020;21(4):975-82.
8. Gunavathy N, Asirvatham A, Chitra A, Jayalakshmi M. Association of CTLA-4 and CD28 Gene Polymorphisms with Type 1 Diabetes in South Indian Population. Immunol Invest. 2019;48(6):659-71.
9. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, et al. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord. 2019;19(1):144-8.
10. Lewis KE, Selby MJ, Masters G, Valle J, Dito G, Curtis WR, et al. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models. Oncoimmunology. 2017;7(1):e1377873.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
12. Olivieri F, Antonicelli R, Spazzafumo L, Santini G, Rippo MR, Galeazzi R, et al. Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. Int J Cardiol. 2014;172(2):e276-8.
13. Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart. 2017;103(1):10-8.
14. Tian T, Liu Y, Zhou X, Song L. Progress in the Molecular Genetics of Hypertrophic Cardiomyopathy: A Mini-Review. Gerontology. 2013;59(3):199-205.
15. Zhong J, He Y, Chen W, Shui X, Chen C, Lei W. Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction. Int J Mol Sci. 2014;15(11):20355-64.
16. Mansouri F. Role of Telemedicine and Telegenetics Framework for the Management of Cancer Patients During the COVID-19. Biointerface Research in Applied Chemistry 2020;11(2):8773-9.
17. Gigli M, Begay RL, Morea G, Graw SL, Sinagra G, Taylor MRG, et al. A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies. Front Cardio Med. 2016;3(21):85-91.
18. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58-67.
19. Hou TZ, Qureshi OS, Sansom DM. Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells. Methods Mol Biol. 2019;1899:87-101.
20. Wang B, Du W, Jia Y, Zhang X, Ma G. Cytotoxic T-lymphocyte-associated protein 4 +49A/G polymorphisms contribute to the risk of type 1 diabetes in children: An updated systematic review and meta-analysis with trial sequential analysis. Oncotarget. 2017;8(6):10553-64.
21. Zhuo Q, Yu B, Zhou J, Zhang J, Zhang R, Xie J, et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci Rep. 2019;9(1):20128.
| Files | ||
| Issue | Vol 21 No 1 (2022) | |
| Section | Brief Communication | |
| DOI | https://doi.org/10.18502/ijaai.v21i1.8621 | |
| Keywords | ||
| Cardiovascular diseases CTLA-4 protein Myocardial infarction | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
